CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Lybalvi (olanzapine/samidorphan) prior authorization for schizophrenia and bipolar I disorder

Defines medical necessity criteria and authorization durations for Lybalvi (olanzapine/samidorphan) for adults with schizophrenia or bipolar I disorder, including baseline and ongoing metabolic monitoring and prior treatment requirements.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyLybalvi (olanzapine/samidorphan) prior authorization for schizophrenia and bipolar I disorder

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJun 1, 2022

Next Review DateN/A

Key ActionObtain and document baseline metabolic panel (glucose, lipid profile, baseline weight) and required prior antipsychotic trial history before requesting authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial authorization duration

12 monthscontinuation authorization duration

>=18minimum patient age

6.6%max allowed weight gain

3 monthsmetabolic review interval

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Lybalvi (olanzapine/samidorphan)

Patients with a known opioid use disorder or those who are utilizing opioids for a chronic health condition are excluded from approval for Lybalvi. This exclusion is based on the coverage criteria requiring the patient to have no documented opioid use disorder and not be receiving chronic opioid therapy at the time of request.

Requests will not meet medical necessity criteria if the required prior treatment trials or baseline metabolic documentation are missing. Specifically, approval requires either a documented trial of generic olanzapine with therapeutic benefit but unacceptable weight gain (≥7% increase from baseline) or inadequate response/intolerance to three preferred oral generic antipsychotics at maximally tolerated doses, plus a documented baseline metabolic panel (glucose, lipid profile, and baseline weight).

For continuation, approval additionally requires documented ongoing metabolic monitoring (glucose, lipid, current weight) that has been reviewed within the last 3 months, and that the patient has not exceeded the allowed weight change threshold (see continuation criteria). Use without these prior trial requirements, without the required baseline or follow-up metabolic documentation, or when weight gain exceeds the policy thresholds is considered not medically necessary under this policy.

Coding & Monitoring Limits

Weight gain limit for continuation — inv-05

Continuation weight thresholdNo more than 6.6% weight increase over baseline start weight

ApplicabilityApplies to continuation authorization (12 months) assessments

Action requiredCompare current weight to baseline start weight and calculate percent change; >6.6% exceeds allowable threshold

Metabolic review interval — inv-06

Required review intervalMetabolic panel must have been reviewed within the last 3 months

Panel components for reviewIncludes glucose, lipid profile, and current weight compared to baseline

ApplicabilityRequired for continuation authorization (12 months)

Provider Actions, Documentation & Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial approvals may be granted for up to 6 months; continuation approvals may be granted for up to 12 months. Submit prior authorization requests with clinical rationale and supporting documentation to avoid delays.

Initial authorization: up to 6 months
Continuation authorization: up to 12 months
Submit requests with supporting clinical documentation

Step Therapy

Step Therapy / Prior Trials

Approval requires documentation of an inadequate response or intolerance to prior antipsychotic therapy. Provide records showing trials of at least three preferred oral generic antipsychotics at maximally tolerated doses, or documentation of why trials were not appropriate (e.g., intolerance, contraindication). Include dates, doses, and clinical response for each trial.

Document trials of ≥3 preferred oral generic antipsychotics at maximally tolerated doses (dates, doses, responses)

Definitions and Baseline Requirements

Baseline metabolic panel — inv-12

Panel componentsGlucose, lipid profile, and patient weight (baseline and ongoing/current)

Baseline requirementBaseline metabolic panel must be documented prior to or at initiation of therapy

Ongoing monitoringMetabolic panel documented since baseline and reviewed at intervals (including within last 3 months for continuation)

Use in decisionsBaseline and follow-up values are used to assess tolerability, clinical response, and adherence to weight-change thresholds

Pharmacotherapy

Pharmacotherapy (Lybalvi)

Medication: Lybalvi (olanzapine/samidorphan) for adults with schizophrenia or bipolar I disorder when criteria met

Background

Lybalvi is a combination product of olanzapine and samidorphan indicated for adults with schizophrenia or bipolar I disorder. Olanzapine is associated with metabolic adverse effects, including weight gain and changes in glucose and lipids; samidorphan is combined to mitigate some of olanzapine’s weight effects. Because of the metabolic risk profile, this policy requires a documented baseline metabolic panel (glucose, lipid profile, baseline weight) prior to initiation and regular metabolic monitoring during treatment to assess tolerability and safety.

The policy balances access with safety by authorizing initial therapy for up to 6 months when initial criteria are met and allowing continuation for up to 12 months when there is documented clinical benefit, tolerability, and ongoing metabolic monitoring (including review within the last 3 months and limits on allowable weight gain).